Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Dennis M, Burnett A, Hills R, Thomas I, Ariti C, Severinsen MT, Hemmaway C, Greaves P, Clark RE, Copland M, Russell N; National Cancer Research Institute (NCRI) acute myeloid leukaemia (AML) Working Group. Dennis M, et al. Among authors: copland m. Br J Haematol. 2021 Jul;194(2):298-308. doi: 10.1111/bjh.17501. Epub 2021 May 7. Br J Haematol. 2021. PMID: 33961292 Clinical Trial.
How I manage priapism in chronic myeloid leukaemia patients.
Rodgers R, Latif Z, Copland M. Rodgers R, et al. Among authors: copland m. Br J Haematol. 2012 Jul;158(2):155-164. doi: 10.1111/j.1365-2141.2012.09151.x. Epub 2012 May 10. Br J Haematol. 2012. PMID: 22571386 Free article. Review.
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.
Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, Byrne JL, de Lavallade H, O'Brien SG, Coffey T, Foroni L, Copland M. Clark RE, et al. Among authors: copland m. Lancet Haematol. 2017 Jul;4(7):e310-e316. doi: 10.1016/S2352-3026(17)30066-2. Epub 2017 May 26. Lancet Haematol. 2017. PMID: 28566209 Free article. Clinical Trial.
Implementing the EffTox dose-finding design in the Matchpoint trial.
Brock K, Billingham L, Copland M, Siddique S, Sirovica M, Yap C. Brock K, et al. Among authors: copland m. BMC Med Res Methodol. 2017 Jul 20;17(1):112. doi: 10.1186/s12874-017-0381-x. BMC Med Res Methodol. 2017. PMID: 28728594 Free PMC article. Clinical Trial.
Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia.
Kinstrie R, Karamitros D, Goardon N, Morrison H, Hamblin M, Robinson L, Clark RE, Copland M, Vyas P. Kinstrie R, et al. Among authors: copland m. Blood Adv. 2016 Dec 14;1(3):160-169. doi: 10.1182/bloodadvances.2016000810. eCollection 2016 Dec 27. Blood Adv. 2016. PMID: 29296933 Free PMC article.
Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.
Cross NCP, White HE, Evans PAS, Hancock J, Copland M, Milojkovic D, Mason J, Craine S, Mead AJ. Cross NCP, et al. Among authors: copland m. Br J Haematol. 2018 Sep;182(6):777-788. doi: 10.1111/bjh.15542. Epub 2018 Aug 20. Br J Haematol. 2018. PMID: 30125955 Free PMC article. Review.
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L, O'Brien SG, Read L, Foroni L, Copland M. Clark RE, et al. Among authors: copland m. Lancet Haematol. 2019 Jul;6(7):e375-e383. doi: 10.1016/S2352-3026(19)30094-8. Epub 2019 Jun 12. Lancet Haematol. 2019. PMID: 31201085 Free article. Clinical Trial.
201 results